4 Biotechnology Stocks to Sell Now

by Portfolio Grader | January 9, 2013 10:00 am

The overall ratings of four Biotechnology stocks are down on Portfolio Grader[1] this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

BioTime’s (AMEX:BTX[2]) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). BioTime is a biotechnology company that focuses on regenerative medicine and blood plasma volume expanders. In Portfolio Grader’s specific subcategories of Equity, Cash Flow, and Sales Growth, BTX also gets an F. As of Jan. 9, 2013, 11.8% of outstanding BioTime shares were held short. For a full analysis of BTX stock, visit Portfolio Grader[3].

Progenics Pharmaceuticals (NASDAQ:PGNX[4]) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock gets F’s in Earnings Momentum, Earnings Revisions, Equity, and Sales Growth. For more information, get Portfolio Grader’s complete analysis of PGNX stock[5].

This is a rough week for Oncothyreon (NASDAQ:ONTY[6]). The company’s rating falls to F from the previous week’s D. Oncothyreon is a biotechnology company that develops therapeutic approaches to cancer management. The stock gets F’s in Earnings Growth, Equity, and Cash Flow. The stock price has dropped 49% over the past month, worse than the 3.8% increase the Nasdaq has seen over the same period of time. To get an in-depth look at ONTY, get Portfolio Grader’s complete analysis of ONTY stock[7].

This week, Immunogen Inc. (NASDAQ:IMGN[8]) drops from C to a D rating. Immunogen develops pharmaceuticals, primarily for the treatment of cancer. The stock also rates an F in Equity. For more information, get Portfolio Grader’s complete analysis of IMGN stock[9].

Louis Navellier’s proprietary Portfolio Grader[10] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[11].

Endnotes:
  1. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  2. BTX: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BTX
  3. For a full analysis of BTX stock, visit Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BTX
  4. PGNX: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=PGNX
  5. For more information, get Portfolio Grader’s complete analysis of PGNX stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=PGNX
  6. ONTY: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ONTY
  7. To get an in-depth look at ONTY, get Portfolio Grader’s complete analysis of ONTY stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=ONTY
  8. IMGN: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=IMGN
  9. For more information, get Portfolio Grader’s complete analysis of IMGN stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=IMGN
  10. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  11. here: http://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: http://investorplace.com/2013/01/4-biotechnology-stocks-to-sell-now-btx-pgnx-onty-3/
Short URL: http://invstplc.com/1nBH2eZ